Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaRichard R. Furman, Susan O’Brien, Paula Cramer et al.|New England Journal of Medicine|2014Cited by 1.7k
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutré, Matthew S. Davids, Michael Y. Choi et al.|Blood|2018Cited by 132
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G. Wierda, Hema Sundar, Jennifer R. Brown et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 84
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024William G. Wierda, Mary A. Dwyer, Jennifer R. Brown et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 83
Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or IdelalisibJeffrey A. Jones, Steven Coutré, Michael Y. Choi et al.|Blood|2016Cited by 58